Tumour metastasis is the primary cause of mortality in cancer patients and remains the key challenge for cancer therapy 1 . New therapeutic approaches to block inhibitory pathways of the immune system have renewed hopes for the utility of such therapies 2 . Here we show that genetic deletion of the E3 ubiquitin ligase Cbl-b (casitas B-lineage lymphoma-b) or targeted inactivation of its E3 ligase activity licenses natural killer (NK) cells to spontaneously reject metastatic tumours. The TAM tyrosine kinase receptors Tyro3, Axl and Mer (also known as Mertk) were identified as ubiquitylation substrates for Cbl-b. Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential, efficiently enhancing anti-metastatic NK cell activity in vivo. Oral or intraperitoneal administration using this TAM inhibitor markedly reduced murine mammary cancer and melanoma metastases dependent on NK cells. We further report that the anticoagulant warfarin exerts anti-metastatic activity in mice via Cbl-b/TAM receptors in NK cells, providing a molecular explanation for a 50-year-old puzzle in cancer biology 3 . This novel TAM/Cbl-b inhibitory pathway shows that it might be possible to develop a 'pill' that awakens the innate immune system to kill cancer metastases.
Tumour metastasis is the primary cause of mortality in cancer patients and remains the key challenge for cancer therapy 1 . New therapeutic approaches to block inhibitory pathways of the immune system have renewed hopes for the utility of such therapies 2 . Here we show that genetic deletion of the E3 ubiquitin ligase Cbl-b (casitas B-lineage lymphoma-b) or targeted inactivation of its E3 ligase activity licenses natural killer (NK) cells to spontaneously reject metastatic tumours. The TAM tyrosine kinase receptors Tyro3, Axl and Mer (also known as Mertk) were identified as ubiquitylation substrates for Cbl-b. Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential, efficiently enhancing anti-metastatic NK cell activity in vivo. Oral or intraperitoneal administration using this TAM inhibitor markedly reduced murine mammary cancer and melanoma metastases dependent on NK cells. We further report that the anticoagulant warfarin exerts anti-metastatic activity in mice via Cbl-b/TAM receptors in NK cells, providing a molecular explanation for a 50-year-old puzzle in cancer biology 3 . This novel TAM/Cbl-b inhibitory pathway shows that it might be possible to develop a 'pill' that awakens the innate immune system to kill cancer metastases.
Genetic ablation of Cbl-b or functional inactivation of its E3 ligase activity in mice results in CD8
1 T-cell-mediated rejection of primary tumours in several different models [4] [5] [6] . In a control experiment subcutaneous injection of TC-1 tumour cells into Cbl-b 2/2 Rag2 2/2 mice, which lack B and T cells, caused a significant delay in tumour growth compared to Cbl-b 1/1 Rag2 2/2 littermates (Fig. 1a) , suggesting that innate immune cells are also involved. Immunohistochemistry revealed increased numbers of NK cells infiltrating the tumours of Cbl-b ) or the C373A KI/KI mutation had no overt effects on NK cell development (Extended Data Fig. 1c, d ).
Cbl-b 2/2 and C373A KI/KI NK cells exhibited significantly increased proliferation and interferon (IFN)-c production when activated in vitro and were also more efficient in killing the prototypic NK cell target tumour cell line RMA-S in vivo (Fig. 1c, d and Extended Data Fig. 1e-j) . In contact with YAC-1 target tumour cells, Cbl-b 2/2 NK cells also displayed a higher capacity to kill, produce IFN-c, degranulate, secrete granzyme B, and to express higher levels of the cytotoxic mediator perforin; knockdown of CBL-B in the human NK cell line NKL also resulted in enhanced cytotoxicity towards Jurkat cells (Extended Data Fig. 2a-h ). NK cell immunodepletion using anti-NK1.1 antibodies and functional blockade of NKG2D (also known as Klrk1) receptors abolished anti-TC-1 tumour responses in Cbl-b 2/2 and C373A KI/KI mice (Extended Data Fig. 3a-c) . Moreover, subcutaneous B16F10 melanomas were slower growing in Cbl-b 2/2 and C373A KI/KI mice; depletion of NK1.1 1 cells reduced this increased survival of melanoma-bearing mice (Extended Data Fig. 3d-i) . Thus, Cbl-b, via its E3 ligase activity, negatively regulates NK cell functions and controls NK-cell anti-tumour responses.
We next analysed whether the absence of Cbl-b can potentiate the anti-metastatic activity of NK cells. Three weeks after intravenous B16F10 melanoma challenge, Cbl-b 2/2 and C373A KI/KI mice exhibited reduced lung metastases and increased survival ( , Cbl-b 2/2 and C373A KI/KI mice (Fig. 1f, g ). NKG2D blockade in Cbl-b 2/2 and C373A KI/KI mice also prevented the reduction of lung melanomas (Extended Data Fig. 4f-i ). Of note, B16F10 melanomas by themselves do not express the NKG2D ligand Rae1, suggesting that this ligand is expressed on the tumour microenvironment. Cbl-b 2/2 and C373A KI/KI mice also exhibited significantly reduced metastases to extrapulmonary organs (Extended Data Fig. 5a-d ), Cbl-b 2/2 Prf1 2/2 double mutants were unable to reduce melanoma metastases (Fig. 1j, k and Extended Data Fig. 5j ). Cbl-b has been implicated in anergic responses of natural killer T (NKT) cells 8 , a cell type that also expresses NK1. 1 (ref. 9) . To provide definitive proof that Cbl-b mutant NK cells directly reject metastatic melanomas, we set up a therapeutic transplantation model. Significantly fewer B16F10 metastases were observed in the lungs of wild-type mice that received Cbl-b 2/2 or C373A KI/KI NK cells, compared to untreated mice and mice receiving Cbl-b 1/1 NK cells ( Fig. 2a-e) . Thus, NK cells lacking Cbl-b, or defective in its E3 catalytic activity, are sufficient to inhibit the progression of lung melanomas and distant metastases.
To extend our findings to a spontaneous tumour metastasis model, Cbl-b mutant animals were crossed to NeuT 1 transgenic mice that develop metastatic breast tumours 10 . Although the onset of palpable mammary tumours was comparable, loss of Cbl-b markedly suppressed the growth of mammary tumours resulting in significantly prolonged overall survival (Extended Data Fig. 6a-d) . Although the number of metastatic lung tumour foci was comparable between Cbl-b 1/2 NeuT 1 and Cbl-b 2/2 NeuT 1 mice, Cbl-b 2/2 NeuT 1 mice showed a significant reduction in the tumour-to-lung area ( Fig. 2f and Extended Data Fig. 6e-g ). In Cbl-b 2/2 NeuT 1 mice we observed a significant accumulation of NK cells within the metastatic foci ( Fig. 2g and Extended Data 6h, i); depletion of NK cells with anti-asialo GM1 antibodies markedly enhanced *** ** *** ** 
and C373A KI/KI mice (f) at day 121. g, B16F10 tumour-to-lung ratios (mean 6 s.e.m.) of control and NK1.1
2/2 (n 5 9/4) and C373A
KI/KI (n 5 7/4) mice. ***P , 0.001 (Student's t-test). h, Representative B16F10 extrapulmonary metastases in a NK1.1 1 cell-depleted mouse. i, Extrapulmonary metastases in control or NK1.1-depleted mice (lines are median, day 116-21) **P , 0.01, ***P , 0.001 (Mann-Whitney U-test). j, k, Representative B16F10 lung metastases (j) and tumour-to-lung ratios (k) (mean 6 s.e.m., day 121) in Cbl-b
2/2 mice. n 5 5/7/8/8. **P , 0.01, ***P , 0.001; NS, not significant (one-way ANOVA, Tukey's post-hoc test). Fig. 7f-h ). Thus, Cbl-b-deficient NK cells can also control metastatic tumours in oncogene-driven mammary cancer.
To identify ubiquitylation substrates, we performed in vitro ubiquitylation reactions on 9,000 human proteins. The transmembrane receptor tyrosine kinase TYRO3 was identified as the top candidate for CBL-Bmediated ubiquitylation (Extended Data Fig. 8a ). Tyro3, together with Axl and Mer, constitute the TAM family of cell-surface tyrosine kinase receptors 11 . In additional in vitro assays using recombinant proteins, we confirmed that CBL-B ubiquitylates all three TAM family proteins ( Fig. 3a and Extended Data Fig. 8b ). Activation of HeLa cells with GAS6, a known ligand for TAM receptors 12 , resulted in recruitment of CBL-B to TAM receptors and AXL ubiquitylation; CBL-B knock-down using short interfering RNA (siRNA) reduced GAS6-induced AXL ubiquitylation (Extended Data Fig. 8c, d) . Thus, TAM receptors are molecular substrates for CBL-B ubiquitylation in vitro and in vivo.
In contrast to TAM triple-mutant mice 13 , loss of Cbl-b had no overt effect on NK cell development (Extended Data Fig. 1c, d ). The absence of Cbl-b, or its enzymatic E3 ligase activity, also had no apparent effect on basal Tyro3, Axl or Mer surface expression in splenic NK cells (Extended Data Fig. 8e ). Because TAM receptors can inhibit macrophage and dendritic cell activation 14 , we proposed that TAM receptors might also negatively regulate NK cells. Gas6 indeed suppressed proliferation and IFN-c production of NKG2D-activated NK cells; Cblb 2/2 NK cells were resistant to this inhibition ( Fig. 3b and Extended Data Fig. 8f ). Mechanistically, whereas Gas6 stimulation resulted in downregulation of all three TAM receptors from the cell surface, this downregulation was impaired in NK cells lacking Cbl-b (Fig. 3c) . Impaired receptor downregulation was confirmed in HeLa cells using siRNAmediated CBL-B knockdown (Extended Data Fig. 8g, h) . Thus, Cbl-b/ TAM receptors constitute an inhibitory pathway for NK cell activation.
To assess whether modulation of this pathway could be used for anti-tumour immunotherapy, we developed a highly selective TAM kinase inhibitor, termed LDC1267. LDC1267 preferentially inhibits Tyro3, Axl and Mer at low nanomolarity, as determined by tracer-based binding assays (Fig. 3d, e) . Selectivity of LDC1267 was further assessed using a cell-free KINOMEscan assay covering 456 kinases ( Fig. 3f and Supplementary Table 1 ). Cellular selectivity was confirmed using a quantitative chemical proteomics approach, cell-based phosphorylation and proliferation assays (Extended Data Fig. 9a-d) . Treatment of NKG2D-activated NK cells with LDC1267 indeed abolished the inhibitory effects of Gas6 stimulation; LDC1267 had no apparent additional effect in Cbl-b-deficient NK cells (Fig. 3g) . In vivo, wild-type mice treated 
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with LDC1267 showed enhanced cytotoxicity towards RMA cells overexpressing the NKG2D ligand Rae-1 (RMA-Rae1) to the same extent as C373A KI/KI mice, but had no effect on the already enhanced NK cytotoxicity in Cbl-b-mutant mice ( Fig. 3h and Extended Data 9e). To provide definitive proof that LDC1267 treatment can license NK cells to kill, we treated B16F10 melanoma-bearing mice with NK cells that were either untreated or treated ex vivo with our TAM inhibitor (Extended Data Fig. 9f ). Adoptive transfer of LDC1267-treated wild-type NK cells significantly increased the anti-tumour response to levels observed in mice transplanted with Cbl-b 2/2 NK cells, but did not increase the anti-metastatic efficacy of Cbl-b-knockout NK cells (Fig. 3i) , reinforcing the notion that Cbl-b acts downstream of TAM receptors for NK cell inhibition. These results indicate that TAM receptor inhibition using LDC1267 unleashes NK cells to kill tumour cells in vivo.
To test whether our novel TAM inhibitor can be used in an in vivo therapeutic setting, we challenged mice with B16F10 melanoma followed by intraperitoneal LDC1267 treatment. LDC1267 markedly reduced metastatic spreading of melanomas; NK1.1 depletion abolished the therapeutic benefits of LDC1267 (Fig. 4a-c) . We next set-up an orthotopic metastatic breast cancer model, that is, injection of 4T1 breast cancer cells into the mammary fat pad of BALB/c mice 15 . LDC1267 treatment significantly reduced the numbers and sizes of 4T1 micrometastases in the liver, without any apparent effect on the primary mammary tumour (Fig. 4d-f and Extended Data Fig. 10a-c) . NK cell depletion using anti-asialo GM1 antibodies resulted in markedly enhanced 4T1 liver metastases and abolished the therapeutic benefits of LDC1267 ( Fig. 4d-f ). We finally tested whether LDC1267 could be also effective in the 4T1 liver metastasis model, when administrated orally (Extended Data Fig. 10d ). Oral LDC1267 significantly reduced 4T1 liver micrometastases (Extended Data Fig. 10e-g ). Thus, using different model systems and different routes of administration, in vivo therapy with the TAM inhibitor LDC1267 consistently reduced metastases dependent on NK cells.
Warfarin is the most widely used oral anticoagulant worldwide 16 and has been known to reduce tumour metastases in mouse and rat models 3, 17 . The underlying mechanisms were largely speculative 18, 19 . Besides its effects on coagulation, warfarin prevents c-carboxylation of TAM ligands, rendering Gas6 unable to activate TAM receptors 20 . We therefore proposed that warfarin could exhibit anticancer effects via modulation of the Gas6/TAM/Cbl-b pathway in NK cells. Administration of low-dose warfarin, which inhibits TAM receptor activity in vivo 21, 22 without affecting coagulation, markedly reduced melanoma metastases to the lungs and distal organs of Cbl-b 1/1 and Cbl-b 1/2 mice but had no apparent effect on Cbl-b-defective mice; the absence of NK1. (n 5 6/7), Cbl-b 2/2 (n 5 4/7) and C373A KI/KI (n 5 8/8) mice. Mean 6 s.e.m. **P , 0.01, *P , 0.05; NS, not significant (Student's t-test). i, j, Relative lung tumour area (i, mean 6 s.e.m.) and extrapulmonary melanoma metastases (j, lines are median) in Cbl-b 1/1 mice treated with vehicle (n 5 15), warfarin (n 5 14), vehicle and anti-NK1.1 antibodies (n 5 5) or warfarin and anti-NK1.1 antibodies (n 5 7). *P , 0.05, ***P , 0.001; NS, not significant (one-way ANOVA, Tukey's post-hoc test for i; Mann-Whitney U-test for j). k, Schematic illustrating the TAM receptor/Cbl-b inhibitory pathway controlling NK cell anti-metastatic activities.
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in enhanced in vivo NK cell cytotoxicity towards their prototypic targets RMA-S and RMA-Rae1 (Extended Data Fig. 10k ). Our data support a coagulation-independent role of warfarin in tumour metastasis that relies on functional TAM receptors/Cbl-b in NK cells.
Our experiments uncover a novel inhibitory role of the E3 ligase Cbl-b in the regulation of NK cell functions via TAM receptors (Fig. 4k) . Releasing the inhibition imposed by this TAM/Cbl-b pathway renders NK cells capable of rejecting tumour metastases. There is high redundancy for TAM receptor functions in immune cells 23 . Because all three TAM receptors are expressed on NK cells 13 , they most likely, as they do in NK cell development 13 , also exert redundant functions in NK cell activation. Indeed, genetic deletion of Tyro3 alone affected neither NK cell activation nor in vivo metastases control by NK cells (not shown). Mechanistically, upon ligand stimulation, Cbl-b is recruited to and ubiquitylates TAM receptors, which in turn appears to control TAM receptor internalization, corroborating the role of Cbl-b and its homologue c-Cbl in receptor tyrosine kinase endocytosis 24 . Of note, c-CBL has been implicated in the ubiquitylation of AXL in human epithelial HLEC cells 25 . Whether Cbl-b affects NK cell activation solely via TAM receptors and/or also directly impinges on other receptor systems needs to be determined.
Current tumour immunotherapies face the challenge of severe side effects 26 . As Cbl-b-knockout mice and mice treated with our TAM blocker do not exert any severe signs of inflammation or autoimmunity, there might be a therapeutic window for Cbl-b/TAM receptor inhibition to mediate tumour rejection without serious cytotoxicity. We also provide a molecular explanation for the longstanding conundrum on how warfarin confers anti-metastatic activity, offering the possibility to reassess the use of vitamin K antagonists such as warfarin in cancer therapy. Importantly, the anti-tumour effects of our TAM inhibitor provide a proof of principle that it might be possible to develop a 'pill' that awakens the innate immune system to kill cancer metastases.
METHODS SUMMARY
Cbl-b and C373A KI/KI mice have been reported previously 7, 27 . Subcutaneous TC-1 and B16F10 tumours were induced by injection of 2.5 3 10 5 tumour cells in the left flank of mice. For 4T1 tumours, 5 3 10 5 4T1 cells were inoculated directly into the third mammary fat pad. Mammary tumours and lung metastases in NeuT 1 mice arise spontaneously 10 . For melanoma metastases, 2.5 3 10 5 B16F10 cells were injected intravenously into the tail veins. Lungs were dissected for tumour quantification and the presence of metastases in any other organ was recorded. For adoptive transfer of NK cells, wild-type C57BL/6J recipient mice were inoculated intravenously with 2.5 3 10 5 B16F10 at day 0, and one day later were either left untreated or inoculated intravenously with 1 3 10 5 purified Cbl-b
KI/KI ex vivo-expanded NK cells. For blocking TAM receptors, mice were orally treated in their drinking water with low doses of warfarin (0.5 mg ml 21 ). The TAM small molecule kinase inhibitor LDC1267 was developed applying rationale design based on the homology modelling and known non-specific TAM receptor kinase inhibitors. To study the therapeutic potential of TAM inhibition, ex vivoexpanded and purified NK cells were treated for 2.5 h with LDC1267 (2.5 mM) or vehicle and intravenously injected into wild-type C57BL/6J recipient mice bearing B16F10 tumours. For 4T1 and melanoma metastases experiments, mice were treated with LDC1267 using daily oral gavage (100 mg kg ). All tumours were quantified blindly on the basis of a histomorphometric analysis using the Definiens Developer XD image analyser software.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. Flow cytometry. Single-cell suspensions were immunostained for 30 min at 4 uC in FACS buffer (PBS-2% FCS). Fc receptors were blocked with anti-CD16/32 antibodies (BD Pharmingen). For staining of NK cells, directly labelled antibodies against NK1.1, DX5, CD3e, Ly49-F, Ly49-D, Ly49I/C, NKG2A/C/E (all from BD Pharmigen) and NKG2D, NKp46, CD27, CD11b, CD122, CD43, Ly49A (eBioscience) were used. For detecting NKG2D ligands, antibodies against Rae1 (pan-specific) and Mult1 were used (both from R&D systems). Tyro3, Axl and Mer surface expression was detected using goat antibodies (all from R&D Systems) followed by Alexa 488 anti-goat secondary antibodies (Life Technologies). Control goat isotype antibodies (R&D Systems) and Tyro3 2/2 NK cells were used as controls. Data were acquired using a multi-colour flow cytometer (FACSCanto or FACSFortessa, BD Biosciences) equipped with the FACSDiva software (BD Biosciences). Data analysis was performed using FlowJo software (Tree Star). Western blotting and immunoprecipitations. Proteins from purified murine NK cells, the human NK92 cell line (a gift from E. Vivier, Marseille) and HeLa cells were extracted using a protein lysis buffer (0.5% NP-40, 150 mM NaCl, 50 mM HEPES, pH 7.8, 1 mM EDTA, pH 8) containing protease inhibitors (Thermo Scientific). 20-40 mg of tissue lysate was resolved on a 4-12% SDS-PAGE, electrotransferred to polyvinylidene difluoride membranes, and probed with anti-Cbl-b (SantaCruz Biotechnology, sc-8006) or anti-Tyro3 (gift from A. L. Prieto) antibodies and as loading control anti-b-actin, anti-GAPDH or anti-b tubulin (Cell Signaling Technology) according to standard procedures. For GAS6 and CBL-B coimmunoprecipitations, HeLa cells were serum-starved overnight and stimulated at 37 uC with 450 ng ml 21 recombinant His-tagged human GAS6 (R&D System) for different time periods, and then lysed as described above. 400 mg of total protein lysates were immunoprecipitated overnight at 4 uC with 25 ml of HisPur cobalt resins (Thermo Scientific) and eluted by boiling at 95 uC for 5 min in reducing loading buffer. Immunoprecipitated and input samples were run on SDS-PAGE gels, transferred to polyvinylidene difluoride membranes and blotted for CBL-B. qRT-PCR. Total cellular RNA was extracted from FACS-sorted primary murine and human NK and T cells using Tri-Reagent (Sigma). Total RNA (1 mg) was reversetranscribed to complementary DNA by using a High-Capacity cDNA Reverse Transcriptions Kit (Applied Biosystems). cDNA was then amplified via qPCR on an ABI PRIM 7000 Sequence Detection System (Applied Biosystems) with TaqMan gene-expression kits for mouse and human Cbl-b and as a normalization control Gapdh (Applied Biosystems). For the detection of Rae1 expression in melanoma lung tumours, RNA samples were purified from dissected healthy lungs and melanoma lung tumours using the Qiagen RNeasy Mini Kit and including DNase I digestion to avoid potential DNA contamination. 1 mg of total RNA was reversed-transcribed using a SuperScript II Reverse Transcriptase Kit (Invitrogen) and oligo-dT primers. Rae1 expression levels were quantified by qPCR (iCycler iQ BioRad) using the iQ SYBR Green Supermix from BioRad, and normalized to Pum1 mRNA levels. Rae1-Forward, TGCCATCGATCCAACGGTACl; Rae1-Reverse, TGGTCCTGGCATCTTTGTCC. Lymphokine activated killer cell (LAK) cultures. For generation of ex vivoexpanded NK cells (LAK), splenocyte suspensions were enriched for NK cells by DX5 1 magnetic separation (MACS, Miltenyi Biotec) and cultured in RPMI media containing 10% FCS (Gibco), 100 IU ml 21 penicillin-streptomycin, 2 mM glutamine, 1 mM Na-pyruvate, 1% MEM non-essential amino acids, 30 mM b-mercaptoethanol (all from Sigma), and 100 ng ml Cr-specific release calculated using the standard formula: percentage cytotoxicity 5 100 3 (sample release 2 spontaneous release)/(100% killed release 2 spontaneous release). Delivery of chemically synthesized siRNA into human NKL cells was accomplished by using the Amaxa Nucleofector system and human NK cell Nucleofector Kits from Lonza Group according to the manufacturer's recommendations. Cbl-b siRNAs were from Dharmacon RNA Technologies (Human no. 10 59-UUUGCUAACGGACCAGUACUU-39 and human no. 11 59-UAAUACCCA AAAUUCGACCUU-39). For assessing NK cytotoxicity in vivo, RMA-S and RMA cells were labelled at 37 uC for 5-10 min with CFSE (Molecular Probes) and eFluor670 (eBioscience), respectively, mixed in a 1:1 ratio and injected intraperitoneally (1 3 10 7 per mouse). For assessing NKG2D-mediated NK cell cytotoxicity in vivo, NK-cell resistant RMA cells and NK-sensitive RMA cells expressing NKG2D ligands (RMA-Rae1) 29 were used. 24 h later, cells were recovered by peritoneal lavage and the relative percentage of sensitive and resistant target cells determined by flow cytometry on gated live cell populations (DAPI (49,6-diamidino-2-phenylindole) negative). Tumour experiments. Of note, only the first TC-1 tumour experiment shown in Fig. 1a was performed in Rag2 2/2 backgrounds. All other tumour experiments were performed in Rag2-sufficient mice and the relevance of NK cells was assessed by immunodepletion approaches and/or NK cell transplant experiments. For subcutaneous tumour models, 2.5 3 10 5 TC-1 or B16F10 cells were subcutaneously injected into the shaved left flank of 8-12-week-old female mice under anaesthesia. Tumour growth was monitored three times per week with a caliper, and mice were euthanized when tumour reached 1 cm 3 in accordance with animal license protocols. For metastatic melanoma studies, mice were intravenously injected into the tail vein with 2.5 3 10 5 B16F10 cells and euthanized 3 weeks later (at day 121). To better assess the quantitative effect of NK cells in Cbl-b-dependent B16F10 tumour rejection, untreated and NK1.1 1 cell-depleted mice were challenged with B16F10 cell using a ten-times-lower dose (2.5 3 10 4 ) and longer periods of time (day 128). To study early tumour responses, mice were intravenously inoculated with 7.5 3 10 5 B16F10 cells and euthanized at day 17. At the LETTER RESEARCH end point of each experiment, mice were euthanized, lungs were collected to determine the relative tumour-to-lung ratios and a careful macroscopic examination of all internal organs was performed to detect the presence of B16F10 extrapulmonary metastases. The prevalence of extrapulmonary metastases for each cohort is defined as the proportion of mice in each cohort showing B16F10 tumour metastasis in other organs than the lung, regardless of the number of organs affected. For mammary tumour studies, mammary gland palpation of NeuT 1 transgenic mice started at day 175 after birth. Tumour growth in all mammary glands was monitored every 5-7 days with a caliper. Mice were euthanized when the total volume of all mammary tumours was $1.5 cm
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. At this point, mammary tumours and lungs were collected, fixed and sectioned to assess tumour growth and lung metastases. As TC-1 cells are derived from female mice, only female animals were used for TC-1 tumour models. Similarly, to study spontaneous mammary tumour metastases in NeuT 1 and 4T1 tumour models, only female mice were used. In all cases, only mice carrying tumours were included in the analysis. Tumour quantification, as described below, was performed blindly. However, for tumour inoculation we were not blinded. Therapeutic transfer of NK cells into melanoma-bearing mice. At day 0, recipient wild-type C57BL/6J mice intravenously received 2. , Cbl-b 2/2 and C373A KI/KI NK cells were sorted from the corresponding LAK cell cultures and adoptively transferred to recipient mice (100,000 cells intravenously per mouse). A control group did not receive LAK cells. Control-and NK-cell transplanted mice were euthanized at day 114 after tumour inoculation and lungs were collected and dissected to determine the number of tumour foci and the relative tumour volume. In addition, the presence of macroscopically visible extrapulmonary metastasis was recorded. Quantification of tumours. For the quantification of B16F10 melanoma metastases, lungs were collected and photographed (two lung images per mouse, one per each lung 'side') using a stereomicroscope (Leica MZ APO). For the quantification of metastatic NeuT 1 mammary carcinomas, lungs isolated from mice bearing NeuT 1 mammary tumours (each mouse with a total mammary tumour volume $1.5 cm 3 to control for the size of the primary tumour) were paraffinembedded and micro-sectioned at three different planes (,350-mm apart) and stained with haematoxylin and eosin. Histological slides (three per mouse) were then scanned on a Mirax Scanner (Zeiss). Tumours in each image were quantified based on a histomorphometric analysis performed automatically using the Definiens image analyser software (Definiens AG, http://www.definiens.com). An algorithm was programmed and executed using this software to discriminate, mark and calculate the number and total area (as pixel) of tumours and 'healthy' surrounding tissue. To assure precision, each image processed by the software was then inspected blindly by two independent scientists (for the B16F10 experiments) or a trained pathologist (for NeuT 1 tumours). To highlight the precision of this selection please see Extended Data Figs 4a, 8a and 13b.The quantification of tumours in each image is relative to the total tissue area and is presented as a percentage, that is, tumour-to-lung ratio 5 [tumour area (pixel)/tumour 1 healthy surrounding tissue area (pixel)] 3 100. Depletion and blocking of immune cells in tumour-bearing mice. Depleting antibodies against CD8 (clone 24.3) and NK1.1 (ref. 30) (clone PK136) as well as NKG2D blocking antibodies (clone MI-6) 31 were produced in-house by hybridoma cultures. The stocks were kindly provided by C. M. Melief, Leiden (CD8 and NK1.1), and D. H. Raulet, Berkeley (NKG2D). Anti-asialo GM1 antibodies were obtained commercially (WAKO). For CD8 1 and NK1.1 1 cell depletion, mice were intraperitoneally injected 4 and 2 days before tumour inoculation with 50 mg anti-CD8 or 100 mg anti-NK1.1 depleting antibodies, respectively. Treatment continued every 5 days after tumour inoculation until the experimental end point. For blocking NKG2D in vivo, mice were injected intraperitoneally with 200 mg of anti-NKG2D blocking antibodies 6 and 3 days before tumour inoculation, and twice a week after tumour inoculation until the end point of the experiment. As NK1.1 receptors are not expressed in the BALB/c genetic background 32 , depletion of NK cells in NeuT 1 and 4T1 tumour models (on a BALB/c background) was accomplished by intraperitoneal injection of anti-asialo GM1 antibodies 33 , according to manufacturer's instructions (WAKO). Administration of anti-asialo GM1 antibodies was initiated when total mammary tumour volume reached 10-100 mm 3 and continued every 5 days until the end point of the experiment. In all cases, control groups were left untreated and cell-specific depletion and NKG2D blocking were confirmed in spleen and blood samples by FACS analysis at day 0 and at the end point of each experiment. Immunohistochemistry. Detection of NK cells was performed with anti-NKp46 antibodies (R&D system) using the automated Leica BOND-III System (Leica Biosystems). The specificity of this antibody has been previously demonstrated 34 and was further controlled in every round of staining by using spleen and lung samples of control and NK-cell depleted mice. TC-1 tumours and lungs from B16F10 and NeuT 1 tumour-bearing mice were fixed overnight in 4% formalin, paraffin-embedded and micro-sectioned at two or three different planes (more than 350-mm apart). Slides were scanned on a Mirax Scanner (Zeiss) and analysed using the Definiens Tissue Studio software (Definiens AG). All tumour areas in each section were analysed and every intratumoral cell was classified as positively or negatively stained. For each mouse two to three tissue slides at different intervals were analysed. The quantification of NKp46 1 cells is relative to the total intratumoral cell numbers and is presented as a percentage 5 [(number of positive cells/ total intratumoral cell number) 3 100]. The representative images shown in the figures were acquired using the Panoramic Viewer Software (3DHistech). Identification of Cbl-b ubiquitylation targets. In vitro ubiquitylation arrays were performed by Invitrogen (ProtoArray Ubiquitin Ligase Identification Profiling Service). Protoarray Human Protein Microarrays containing over 9,000 proteins were incubated with purified ATP, E1 activating enzymes (100 nM), haemagglutinin (HA)-Ub (100 mg ml 21 ), the E2 UbcH5b (1 mM) and either wild-type CBL-B or C373A mutant CBL-B (100 nM, in duplicates). To control for ubiquitylationindependent signals, an array was incubated with just detection antibodies (negative control). To exclude E2-specific ubiquitylation substrates, an array was run with all reagents and enzymes except for the E3 ligase (CBL-B). Ubiquitylation substrates were detected with mouse anti-HA antibodies followed by fluorescently labelled anti-mouse antibodies. Arrays were then scanned and pixel intensity data for each protein spot was acquired using GenePiX software. A comparative analysis of the relative fluorescent signal of every spot in each array allowed the identification of putative CBL-B ubiquitylation substrates. In vitro ubiquitylation assays. To confirm the array data, cell-free in vitro ubiquitylation assays were performed. In brief, full-length Flag-tagged human TYRO3, AXL and MER (all from Origene) were incubated at 30 uC for 1 h in a reaction mixture (20 ml) containing ubiquitylation solution (Enzo Biomol), 1 mM ATP, 1 mM DTT, 20 U ml 21 inorganic pyrophosphatase, 5 mM Mg-ATP, 2.5 mM ubiquitin (Enzo Biomol), 100 nM His-Uba1 (home-made), 2.5 mM UbcH5B (Enzo Biomol) and 100 nM full-length human CBL-B (Novus Biologicals). As a control, the same reactions were performed in the absence of recombinant CBL-B. The reaction was quenched by adding 20 ml of 23 reducing gel loading buffer and heating at 95 uC for 5 min. Finally, the samples were immunoblotted with antiubiquitin (sc-8017, SantaCruz Biotechnology) or anti-Flag antibodies (Sigma). For loading controls, samples were blotted with anti-Cbl-b (sc-8006, SantaCruz Biotechnology) and anti-Flag antibodies (Sigma). Ubiquitination of AXL in HeLa cells. Delivery of chemically synthesized siRNA into HeLa cells (gift from J. P. Fededa) was performed using Lipofectamine RNAiMAX Transfection Reagent (Sigma), ON-TARGETplus SMARTpool for Human CBL-B, and as a control an ON-TARGETplus NON-targeting Pool (both from Thermo Scientific, L-003004-00-0005 and D-001810-10-05) according to manufacturer's protocol. CBL-B knockdown was verified by western blotting. 48 h after siRNA transfection, HeLa cells were serum-starved overnight and then stimulated at 37 uC with 500 ng ml 21 recombinant human GAS6 (R&D Systems) for different time periods. Cells were then placed on ice, washed in ice-cold PBS and lysed in RIPA buffer (Sigma) containing protease inhibitors (Thermo Scientific) and 10 mM N-ethylmaleimide (Sigma). 600-1,000 mg of total protein lysates were immunoprecipitated overnight at 4 uC with 4 mg anti-Axl antibodies (Santa Cruz Biotechnology, sc-1097) and 25 ml of recombinant Protein G-Sepharose 4B conjugates (Invitrogen). After four washes, elution from the beads was performed by adding 20 ml of 23 reducing gel loading buffer and heating at 95 uC for 5 min. Immunoprecipitated and input samples (45 mg) were run on SDS-PAGE gels, transferred to nitrocellulose membranes and blotted with anti-ubiquitin (P4D1, sc-8017) and anti-Axl (sc-1097) antibodies in 5%BSA-TBS-Tween according to standard protocols. TAM receptor internalization. Receptor internalization was performed following a protocol described previously 35 . In brief, freshly isolated mouse splenocytes and HeLa cells (serum-starved for 16 h) were incubated on ice for 1 h with 200 ng ml 21 of recombinant mouse or human Gas6, respectively (R&D Systems). After washing, cells were re-suspended in 0.2% BSA medium and incubated at 37 uC for the indicated time periods. Cells were then placed on ice, washed with ice-cold PBS, incubated for 5 min with cold acidic buffer to remove any bound ligand (100 mM NaCl, 50 nM glycine, pH 2.5), and subsequently washed twice in icecold PBS. HeLa cells were mechanically detached using a cell-scraper. Cell suspensions were then stained on ice for 45 min with anti-Axl, anti-Tyro3, anti-Mer and a control goat isotype antibodies (all from R&D Systems) in 0.2% BSA-PBS containing 0.1% sodium azide, followed by incubation with anti-goat Alexa 488 secondary antibodies. Splenocyte suspensions were also stained for anti-NK1.1 and anti-TCR-b (BD Bioscience) and DAPI (Sigma ). The amount of receptor present at the cell surface at each time point is displayed as a percentage of the relative FITC mean RESEARCH LETTER intensity value in relation to the control 0-min time point (5 100% surface expression). Generation of the TAM receptor tyrosine kinase inhibitor LDC1267. LDC1267 was rationally designed as type II kinase inhibitor using a pharmacophore-based back pocket approach. Hundreds of compounds from the series of quinolines were synthesized and optimized using a cell-based Axl autophosphorylation assay as the primary enzymatic read-out. The synthesis of the chemical series of 1-nitrogen-heterocyclic-2-carboxamides including the current lead N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide (LDC1267) has been recently reported 36 . LDC1267 was synthesized as follows: to a solution of 4-ethoxy-1-(4-fluoro-2-methyl-phenyl) pyrazole-3-carboxylic acid (127 mg, 0.48 mmol, 1.5 equiv.) in dry dichloromethane (2 ml) at 0 uC was added slowly oxalyl chloride (63 ml, 0.72 mmol, 2.3 eq.) and a drop of dry dimethylformamide (10 ml). The cooling bath was removed and the mixture was stirred for 1.5 h at room temperature (20 uC). Solvents were removed in vacuo, the crude material resolved in dry toluene and evaporated under reduced pressure to yield the acid chloride. The acid chloride was solved in dry pyridine (2 ml) at 0 uC and 4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluoroaniline (100 mg, 0.32 mmol, 1.0 equiv.) was added. After stirring for 2 h at room temperature, water was added and solvents were removed under reduced pressure. The crude product was purified by flash chromatography on silica gel (DCM/MeOH 5 100:0 to 5:1) to yield the desired product LDC1267 (136 mg, 0.24 mmol, 76%). To prepare the HCl-salt, LDC1267 (125 mg) was solved in acetonitrile (3 ml) and water (3 ml). After adding aqueous HCl-sol (c 5 1 mol l 21 , 0.22 ml, 1.0 eq.) and stirring for 1 h, the mixture was lyophilized yielding the HCl-salt of LDC1267 (132 mg). To establish the inhibitory profile of LDC1267, this compound was tested extensively using three selectivity assays to define its biochemical and cellular selectivity. First, we accessed a broad kinase inhibition panel of 456 kinases (including 66 natural occurring kinase mutations; conducted by DiscoverX). 39 out of 456 tested kinases were inhibited to a lower than 10% remaining activity at 1 mM concentration of LDC1267. Thus, at the level of a cell-free assay, LDC1267 inhibits less than 10% of the tested kinome at a concentration which is roughly 100 times higher than the IC 50 value for Axl. Second, we tested the cellular selectivity of LDC1267 by using a quantitative chemical proteomics approach 37, 38 . Lysates from Hs578t cells were incubated with an unspecific kinase inhibitor covalently bound to a matrix (experiments were conducted by Kinaxo/Evotec). Elution with up to 10 mM LDC1267 identified two high-affinity protein targets (K D about 30 nM), namely Axl and Met. This correlates well with the cellular inhibition of Axl phosphorylation using LDC1267 in these cells (IC 50 value is ,0.010 mM). Of note, Tyro3 is not expressed in Hs578t cells. In addition, MAP2K5, Abl, Fer and Src also bound to the matrix, but with approximately tenfold lower affinity. Other kinase targets, which were identified in the cell-free KINOMEscan selectivity assay as LDC1267 binders (Aurora, Lck, Ddr1, Lok, Blk, Map4k5 or Cdk8) did not bind the kinase inhibitor matrix, although they are expressed in Hs578t cells. Similarly, kinases such as Ddr2, Mst1, Plk4, Slk and Tec, also identified in the KINOMEscan experiment with reduced affinities (#20% remaining activity at 10 mM LDC1267), did not bind to LDC1267 in our chemoproteomics experiment. This demonstrates that LDC1267 is even more selective at the cellular level when compared to its biochemical profile.
Third, we investigated the effects of LDC1267 (up to 30 mM) on proliferation of 95 different cancer cell lines. LDC1267 did not affect proliferation of 84 cell lines and moderately affected proliferation of 11 cell lines (best IC 50 value at ,5 mM; average IC 50 value for those 11 cell lines is ,15 mM). We also tested more than 1,500 different kinase inhibitors in the same panel of cancer cell lines. In these assays non-specific kinase inhibitors like staurosporine or dasatinib inhibit proliferation of (nearly) every cell line with IC 50 values below 0.1 mM. By contrast, specific kinase blockers inhibit proliferation of only a few cell lines (for example, K562 cells in the case of imatinib). LDC1267 does not affect cell proliferation at all at a concentration .1 mM, a concentration at which in all our assays TAM receptor tyrosine kinases are completely blocked.
Thus, LDC1267 is a highly selective kinase inhibitor binding to the TAM receptor tyrosine kinases and c-Met. Finally, we compared the cellular specificity/ activity of LDC1267 and 15 close chemical analogues for Axl or c-Met using cellbased phosphorylation assays. The biochemical Axl K d values were in the same range as the cellular IC 50 values for Axl autophosphorylation. By contrast, this was not observed for c-Met. LDC1267 and close analogues had cellular c-Met autophosphorylation IC 50 values about one order of magnitude higher than the biochemical values. Therefore, the inhibition of Axl by LDC1267 can be numerically directly translated into Axl inhibition in cells, whereas a similar effect on c-Met autophosphorylation requires tenfold higher concentrations indicating an additional cellular specificity for LDC1267. Thus, LDC1267 is a highly selective inhibitor for TAM receptor tyrosine kinases with a type II binding mode (tight binding with slow k on and k off rates). Kinase binding assays. For optimization of Axl/TAM receptor inhibitors, an Axl binding assay was established (HTRF method; Kinase tracer 236). This assay is based on the binding and displacement of the Alexa Fluor 647-labelled Kinase tracer 236 (Life Technologies) to each glutathione S-transferase (GST)-tagged kinase used in the binding assay. Binding of the tracer to the kinase was detected by using europium (Eu)-labelled anti-GST antibodies. Simultaneous binding of both the fluorescent tracer and the Eu-labelled antibodies to the GST-tagged kinase generates a fluorescence resonance energy transfer (FRET) signal. Binding of inhibitor to the kinase competes for binding with the tracer, resulting in a loss of the FRET signal. For the assay, the compound was diluted in 20 mM HEPES, pH 8.0, 1 mM DTT, 10 mM MgCl 2 and 0.01% Brij35. Then, the kinase of interest (5 nM final concentration), fluorescent tracer (15 nM final concentration; purchased from Invitrogen) and LanthaScreen Eu-anti-GST antibody (2 nM final concentration; purchased from Invitrogen) were mixed with the respective compound dilutions (from 5 nM to 10 mM) and incubated for 1 h. The FRET signal was quantified using an EnVision Multilabellreader 2104 (Perkin Elmer).
Comparing the results for more than 200 compounds in the homogeneous time-resolved fluorescence (HTRF) assay with the results from cellular phosphorylation assays for Axl/TAM receptor kinase inhibitors from different structural classes revealed a clear correlation for the two assay formats. Reference compounds such as BMS-777607/ASLAN002, sunitinib and staurosporine showed inhibitory activities as expected. Most importantly, we observed almost no numerical shift in activity when using either the biochemical HTRF method or the cellular autophosphorylation assay for measuring Axl activity. This indicates that LDC1267 binds with a mode of action which is independent of the ATP concentration and C373A KI/KI mice were treated three times, 12 h apart, by oral gavage with vehicle (70% PEG400:30% H 2 O) or 100 mg kg 21 LDC1267 before the intraperitoneal inoculation of a mixture of differentially labelled RMA:RMA-Rae1 cells. 24 h after inoculation cytotoxicity towards RMA-Rae1 cells was analysed as described above. For adoptive NK cell transfers, wild-type C57BL/6J recipient mice were inoculated intravenously with 2. ). 12 h after the last dose, LDC1267 plasma concentrations were measured using liquid chromatography-mass spectrometry-based analytics. Control mice were treated with vehicle (70% PEG400:30% H 2 O for oral gavage or 90% PEG400:10% DMSO for intraperitoneal administration). For studying the dependence of NK cells in this 4T1 tumour model, NK cells were depleted using
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anti-asialo GM1 antibodies starting at day 25 before tumour inoculation. Injections of the depleting antibodies were continued every 5 days until the experimental end point. Micro-metastases into the lung and liver were analysed at day 121 (for oral gavage treatment) and day 116 (for intraperitoneal treatment) after initial 4T1 challenge. Livers and lungs were paraffin-embedded, micro-sectioned, haematoxylin and eosin-stained and scanned on a Mirax Scanner (Zeiss). For this particular tumour quantification in the liver and to exclude inflammatory foci, a manual selection was preferred instead of an automated one. Using the Definiens Developer XD Software a trained animal pathologist established the number and relative tumour area of 4T1 micro-metastasis in each tissue section. For this, 10-22 different image fields (0.5 mm 2 each) were blindly selected throughout the tissue and each tumour within the image field was precisely marked. To highlight the precision of this selection please see Supplementary Fig. 13b , intraperitoneally) started 24 h later (day 11) and continued every 12 h, until the experimental end point at day 114. Control mice were treated with vehicle only (90% PEG400:10% DMSO). For studying the role of NK cells, anti-NK.1.1 antibodies (clone PK136) were used following the immunodepletion protocol described above. Mice were euthanized at day 114 to quantify lung melanoma metastases using the Definiens analyser Software. At the time of dissection a careful examination of all internal organs was performed to determine the presence of extrapulmonary metastases. Warfarin studies. Gas6 inhibition in vivo was performed as described previously 22 . In brief, mice were treated in their drinking water with 0.5 mg l 21 warfarin (Coumadin, Bristol-Myers Squibb) dissolved in an ethanol/glycerol solution. Control mice were treated with the ethanol/glycerol vehicle solution only. Solutions were prepared fresh every 3-4 days. The treatment started at day 25 before tumour inoculation and continued until the end point of the experiment. Warfarin-and vehicle-treated mice were intravenously injected with B16F10 tumour cells as described above. To determine the role of NK cells in warfarin anti-metastatic activity, vehicle-and warfarin-treated mice were either left untreated or depleted of NK cells by administration of anti-NK1.1 depleting antibodies. At day 116, mice were euthanized and melanoma metastases to the lung and extrapulmonary organs quantified. Prothrombine time was measured on plasma samples collected from warfarin-treated and vehicle-treated mice at the experimental end point (day 116) using an Amelung KC coagulometer (performed by In vitro-Labour GmbH). Warfarin effects on NK cytotoxicity were also evaluated by intraperitoneal injection of a mixture of NK-cell-resistant and -sensitive cells (RMA:RMA-S or RMA:RMA-Rae1) into warfarin-and vehicle-treated mice as described above. Statistical analyses. Unless otherwise stated data are shown as mean values 6 standard error of the mean (s.e.m). The numbers of mice per group used in each experiment are annotated in the corresponding figure legends as n. All experiments shown were reproduced 2-5 independent times. Figures and statistical analyses were generated using GraphPad Prism 5 (GraphPad Software). For tumour experiments, only mice that developed tumours were included in the analysis and all tumour quantifications were performed blindly by using the Definiers Software analyser. Mice were allocated to experimental groups on the basis of their genotype and randomized within the given sex-and age-matched group. Given that our mice were inbred and matched for age and sex, we always assumed similar variance between the different experimental groups. We did not perform an a priori sample size estimation but always used as many mice per group as possible in an attempt to minimize type I and type II errors. Critical experiments have high n numbers and were repeated multiple times. Data were first analysed for normal distribution using D'Agostino and Pearson omnibus normality tests. Normally distributed data was analysed using unpaired two-tailed Student's t-test for single comparisons, and one-way or two-way ANOVA for multiple comparisons. ANOVA analyses were followed by Dunnett's, Bonferroni's or Tukey's post-hoc tests. Ordinal and not normally distributed data was analysed using unpaired two-tailed MannWhitney U-test for single comparisons or Kruskal-Wallis test followed by Dunn's post-hoc test for multiple comparisons. The prevalence of secondary metastases was analysed using the Chi-squared test. Overall survival to tumour challenge was analysed in Kaplan-Meier curves using a log-rank test. The statistical test used and P values are indicated in each figure legend. P # 0.05 was considered to indicate statistical significance. *P # 0.05, **P # 0.01, ***P # 0.001. NS, not significant. Cr-release assay (c) (mean values 6 s.e.m., n 5 3). *P , 0.05, **P , 0.01, ***P , 0.001 (Student's t-test). 2/2 (n 5 7) and Cbl-b 2/2 Prf1 2/2 (n 5 11) mice at the experimental end point (day 121). *P , 0.05, ***P , 0.01 (Mann-Whitney U-test).
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